Author:
Iihara Hirotoshi,Fujii Hironori,Yoshimi Chiaki,Kobayashi Ryo,Matsuhashi Nobuhisa,Takahashi Takao,Yoshida Kazuhiro,Suzuki Akio
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference22 articles.
1. Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann Oncol 8:837–855
2. Kono A, Hara Y (1991) Conversion of CPT-11 into SN-38 in human tissues. Gan To Kagaku Ryoho 18:2175–2178
3. Kawato Y, Aonuma M, Matsumoto K (1991) Production of SN-38, a main metabolite of the camptothecin derivative CPT-11, and its species and tissue specificities. Gan To Kagaku Ryoho 6:899–907
4. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, Ratain MJ (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576–582
5. Sai K, Sawada J, Minami H (2008) Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28. Yakugaku Zasshi 128:575–584
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献